SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-1206
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo

Cellular Physiology and Biochemistry
Physiology
2019English

Dual Inhibition of BRD4 and PI3K-AKT by SF2523 Suppresses Human Renal Cell Carcinoma Cell Growth

Oncotarget
Oncology
2017English

KRASG12D Promotes Immunosuppression in Colorectal Cancer

Cancer Discovery
Oncology
2019English

Elimination of Tumor by CD47/PD-L1 Dual-Targeting Fusion Protein That Engages Innate and Adaptive Immune Responses

mAbs
AllergyImmunology
2017English

PI3K- Inhibitor Produces Long-Lasting Responses

Cancer Discovery
Oncology
2013English

Prostate Cancer Stem Cells Are Targets of Both Innate and Adaptive Immunity and Elicit Tumor-Specific Immune Responses

OncoImmunology
OncologyAllergyImmunology
2013English

CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

Clinical Cancer Research
Cancer ResearchOncology
2011English

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Nab-Paclitaxel Antitumor Response in Experimental Gastric Cancer

International Journal of Oncology
Cancer ResearchOncology
2013English

Pd32-01 Pre-Clinical Rationale for Combination Pi3k and Brd4 Inhibition in Advanced Prostate Cancer

Journal of Urology
Urology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy